Tìm theo
Linezolid
Các tên gọi khác (5 ) :
  • Linezolid
  • Linezolid
  • Linezolide
  • Linezolidum
  • N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
Thuốc trị ký sinh trùng, chống nhiễm khuẩn
Thuốc Gốc
Small Molecule
CAS: 165800-03-3
ATC: J01XX08
ĐG : Fresenius Kabi AB , http://www.fresenius-kabi.com
CTHH: C16H20FN3O4
PTK: 337.3461
Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). The drug works by inhibiting the initiation of bacterial protein synthesis.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C16H20FN3O4
Phân tử khối
337.3461
Monoisotopic mass
337.143784348
InChI
InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
InChI Key
InChIKey=TYZROVQLWOKYKF-ZDUSSCGKSA-N
IUPAC Name
N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
Traditional IUPAC Name
linezolid
SMILES
CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
Độ hòa tan
3 mg/mL
logP
0.9
logS
-2.4
pKa (strongest acidic)
14.45
pKa (Strongest Basic)
-0.66
PSA
71.11 Å2
Refractivity
84.47 m3·mol-1
Polarizability
34.06 Å3
Rotatable Bond Count
4
H Bond Acceptor Count
5
H Bond Donor Count
1
Physiological Charge
0
Number of Rings
3
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Susceptible organisms include methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes. Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit. Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, associated with 23S rRNA alterations during treatment have been reported. Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between linezolid and other classes of antibiotics is unlikely.
Cơ Chế Tác Dụng : Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). The drug works by inhibiting the initiation of bacterial protein synthesis. Linezolid is a synthetic antibacterial agent of the oxazolidinone class of antibiotics. It has in vitro activity against aerobic Gram positive bacteria, certain Gram negative bacteria and anaerobic microorganisms. It selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Specifically, linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process. The results of time-kill studies have shown linezolid to be bacteriostatic against enterococci and staphylococci. For streptococci, linezolid was found to be bactericidal for the majority of strains. Linezolid is also a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
Dược Động Học :
▧ Absorption :
Linezolid is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
▧ Volume of Distribution :
* 40 to 50 L [healthy adult volunteers]
▧ Protein binding :
31%
▧ Metabolism :
Linezolid is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminoethoxyacetic acid metabolite (A), and the hydroxyethyl glycine metabolite
▧ Half Life :
4.5-5.5 hours
Độc Tính : Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.
Chỉ Định : For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.
Tương Tác Thuốc :
  • Bezafibrate MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like linezolid.
  • Brimonidine MAO Inhibitors like linezolid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
  • Buprenorphine Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like linezolid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
  • Citalopram Combination associated with possible serotoninergic syndrome
  • Desvenlafaxine Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
  • Dobutamine Possible increase of arterial pressure
  • Dopamine Possible increase of arterial pressure
  • Ephedra Possible increase of arterial pressure
  • Ephedrine Possible increase of arterial pressure
  • Epinephrine Possible increase of arterial pressure
  • Escitalopram Combination associated with possible serotoninergic syndrome
  • Fenoterol Possible increase of arterial pressure
  • Fluoxetine Linezolide, a MAO inhibitor, may increase the serotonergic effect of fluoxetine, a SSRI. Increased for of serotonin syndrome. Concomitant therapy should be avoided.
  • Fluvoxamine Combination associated with possible serotoninergic syndrome
  • Isoprenaline Possible increase of arterial pressure
  • Mephentermine Possible increase of arterial pressure
  • Metaraminol Possible increase of arterial pressure
  • Methoxamine Possible increase of arterial pressure
  • Nefazodone Combination associated with possible serotoninergic syndrome
  • Norepinephrine Possible increase of arterial pressure
  • Orciprenaline Possible increase of arterial pressure
  • Paroxetine Combination associated with possible serotoninergic syndrome
  • Phenylephrine Possible increase of arterial pressure
  • Phenylpropanolamine Possible increase of arterial pressure
  • Pirbuterol Possible increase of arterial pressure
  • Procaterol Possible increase of arterial pressure
  • Pseudoephedrine Possible increase of arterial pressure
  • Salbutamol Possible increase of arterial pressure
  • Sertraline Combination associated with possible serotoninergic syndrome
  • Terbutaline Possible increase of arterial pressure
  • Tetrabenazine Tetrabenazine may increase the adverse/toxic effects of Linezolid. Concomitant therapy is contraindicated.
  • Tolcapone Tolcapone and Linezolid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
  • Tramadol Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Linezolid.
  • Tranylcypromine The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Linezolid. These agents should not be administered within 14 days of each other.
  • Trazodone Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Trimipramine Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
  • Venlafaxine Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
  • Vilazodone MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.
  • Zolmitriptan The MAO inhibitor, linezolid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing linezolid are contraindicated.
Liều Lượng & Cách Dùng : Solution - Intravenous
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Verisfield
    Sản phẩm biệt dược : Antizolid
  • Công ty : Orion
    Sản phẩm biệt dược : Linosept
  • Công ty : Orion
    Sản phẩm biệt dược : Linozid
  • Công ty : Abbott
    Sản phẩm biệt dược : Lizbid
  • Công ty : Molekule
    Sản phẩm biệt dược : Lizemox
  • Công ty : Glenmark
    Sản phẩm biệt dược : Lizolid
  • Công ty : Corona
    Sản phẩm biệt dược : Xolid
  • Công ty : Hemofarm
    Sản phẩm biệt dược : Zenix
  • Công ty : Biofarma
    Sản phẩm biệt dược : Zizolid
  • Công ty : FDC
    Sản phẩm biệt dược : Zodlin
  • Công ty : Teva
    Sản phẩm biệt dược : Zolinid
  • Công ty : Pfizer
    Sản phẩm biệt dược : Zyvox
  • Công ty : Pfizer
    Sản phẩm biệt dược : Zyvoxam
  • Công ty : Pfizer
    Sản phẩm biệt dược : Zyvoxid
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00601
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=441401
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504452
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C08146
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00947
ChemSpider
http://www.chemspider.com/Chemical-Structure.390139.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50116067
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0009-5137-01
PharmGKB
http://www.pharmgkb.org/drug/PA450233
Wikipedia
http://en.wikipedia.org/wiki/Linezolid
RxList
http://www.rxlist.com/cgi/generic3/linezolid.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/zyv1556.shtml
Drugs.com
http://www.drugs.com/cdi/linezolid.html
... loading
... loading